Survodutide
Survodutide
A dual GLP-1/glucagon receptor agonist developed by Zealand Pharma and Boehringer Ingelheim. Shows promise for obesity and NASH treatment.
Typical Cost
Not yet priced
Status
Research
Peptide Profile
Survodutide
Mechanism of Action
Activates GLP-1 receptors for appetite suppression and glucagon receptors for increased energy expenditure and improved lipid metabolism. Uniquely effective for liver fat reduction.
Common Dosages
subcutaneous
0.3-4.8mg
Weekly · Ongoing
Benefits
Significant weight loss
Liver fat reduction
Improved NASH markers
Better glycemic control
Enhanced energy expenditure
Side Effects
Nausea
Vomiting
Diarrhea
Injection site reactions
Gallbladder issues
Key Research
Survodutide phase II in obesity
Average 14.9% weight loss at 46 weeks with superior NASH improvement
Regulatory Status
Phase III trials for obesity and NASH. Not yet FDA-approved.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠MEN2 syndrome
- ⚠Pregnancy/breastfeeding
- ⚠Severe liver disease
For GLP-1 users with fatty liver concerns, survodutide may offer dual benefits. SeraVia Detox+ Shield supports liver health during weight loss.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.